Mahfuzur Rahman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mahfuzur Rahman has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Naoki Miura
Joint Graduate School of Veterinary Medicine, Kagoshima University, Kagoshima 890-0065, Japan
18 shared publications - Paul M. Sondel
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
16 shared publications - Tracy J. Berg
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
16 shared publications - Zachary S. Morris
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA
16 shared publications - Caroline P. Kerr
Department of Radiology, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA
15 shared publications - Irene M. Ong
Departments of Biostatistics and Medical Informatics, School of Medicine and Public Health, Univ. of Wisconsin-Madison
15 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
CD4 depletion increases tumor growth in mice treated with TRT+DCP+ISV.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
CD4 depletion increases tumor growth in mice treated with TRT+DCP+ISV.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
ISV stimulates systemic immunity against antigen-matched metastases.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
ISV stimulates systemic immunity against antigen-matched metastases.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
NK cells infiltrate tumors in mice treated with TRT+DCP+ISV or TRT+ISV.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
NK cells infiltrate tumors in mice treated with TRT+DCP+ISV or TRT+ISV.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Data from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
Focal radiotherapy can provide an in situ vaccine (ISV) effect that may prime adaptive antitumor immunity, which can be augmented by combination with intratumoral immune adjuvants and systemic immune checkpoint inhibition. However, propagation of an antitumor immune response is not consistently achieved in metastatic disease. Delivery of low-dose targeted radionuclide therapy (TRT) can promote clonal expansion and propagation of antitumor immune responses. Therefore, in this study, we combined dual immune checkpoint blockade (DCP; anti–PD-L1 and anti–CTLA-4) with ISV (focal radiotherapy with intratumoral injection of tumor-specific monoclonal antibody and IL2) to prime and with low-dose TRT to propagate antitumor immunity. C57BL/6 mice were engrafted with primary and secondary tumors and intravenously injected with tumor cells to model advanced metastatic disease. Mice with poorly immunogenic, syngeneic MOC2 head and neck squamous cell carcinomas or B78 melanomas received monotherapy or double or triple combinations of low-dose TRT, DCP, and primary tumor–targeted ISV. When compared with dual or monotherapies, TRT + DCP + ISV eradicated bulky well-established tumors, prevented development of lung metastases from circulating tumor cells, and extended survival (P < 0.01). TRT + DCP + ISV conferred tumor-specific immune memory, enabling uniform rejection of tumor re-engraftment. TRT + DCP + ISV activated innate and adaptive immune responses in the primary and secondary tumors. Overall, these data highlight TRT + DCP + ISV as a promising approach to prime and propagate antitumor immunity and promote response to checkpoint inhibition.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
Focal radiotherapy can provide an in situ vaccine (ISV) effect that may prime adaptive antitumor immunity, which can be augmented by combination with intratumoral immune adjuvants and systemic immune checkpoint inhibition. However, propagation of an antitumor immune response is not consistently achieved in metastatic disease. Delivery of low-dose targeted radionuclide therapy (TRT) can promote clonal expansion and propagation of antitumor immune responses. Therefore, in this study, we combined dual immune checkpoint blockade (DCP; anti–PD-L1 and anti–CTLA-4) with ISV (focal radiotherapy with intratumoral injection of tumor-specific monoclonal antibody and IL2) to prime and with low-dose TRT to propagate antitumor immunity. C57BL/6 mice were engrafted with primary and secondary tumors and intravenously injected with tumor cells to model advanced metastatic disease. Mice with poorly immunogenic, syngeneic MOC2 head and neck squamous cell carcinomas or B78 melanomas received monotherapy or double or triple combinations of low-dose TRT, DCP, and primary tumor–targeted ISV. When compared with dual or monotherapies, TRT + DCP + ISV eradicated bulky well-established tumors, prevented development of lung metastases from circulating tumor cells, and extended survival (P < 0.01). TRT + DCP + ISV conferred tumor-specific immune memory, enabling uniform rejection of tumor re-engraftment. TRT + DCP + ISV activated innate and adaptive immune responses in the primary and secondary tumors. Overall, these data highlight TRT + DCP + ISV as a promising approach to prime and propagate antitumor immunity and promote response to checkpoint inhibition.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
Figure S6 from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
Figure S6 from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
MHC-1, FAS, and PD-L1 expression on immune cell subsets.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
MHC-1, FAS, and PD-L1 expression on immune cell subsets.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
Rechallenge tumor volumes and gating strategies.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
Rechallenge tumor volumes and gating strategies.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
MHC-1 is expressed on tumor cells after TRT+DCP+ISV.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
MHC-1 is expressed on tumor cells after TRT+DCP+ISV.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
TRT+DCP+ISV activates a potent T cell immune memory response.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
TRT+DCP+ISV activates a potent T cell immune memory response.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
Enrichment of Th1, Th2, and apoptosis genes with TRT+DCP+ISV.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
Enrichment of Th1, Th2, and apoptosis genes with TRT+DCP+ISV.